BHV-8000

PreclinicalSmall molecule

BBiohaven Therapeutics Ltd.

BHV-8000 is one of 46 small molecule programs targeting Parkinson disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseRecruiting

Parkinson DiseasePreclinical

Recruiting

Competition

Competitive Landscape

92 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Brintellix

Takeda

Approved

1 2

Aricept

Eisai

Approved

1 3

Exelon

Novartis

Approved

1 4

Northera

Lundbeck

Approved

1 5

Myrbetriq

Astellas

Approved

1 6

Medrol

Pfizer

Approved

1 7

Avelox

Nicorette

Epidiolex

Ritalin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Parkinson Disease

NCT06976268

Clinical

Trials by Indication[1]

Parkinson disease1 trial

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Recruiting·BBiohaven Therapeutics Ltd.·Preclinical·NCT06976268·550 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BHV-8000. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BHV-8000 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BHV-8000. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biohaven Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBiohaven Therapeutics Ltd.

BHV-8000

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Parkinson disease1 trial

References

Drug Info

Quick Facts

Related News